View Item 

Show simple item record

Considerations for Screening Live Kidney Donors for Endemic Infections: A Viewpoint on the UNOS Policy

dc.contributor.authorLevi, M. E.en_US
dc.contributor.authorKumar, D.en_US
dc.contributor.authorGreen, M.en_US
dc.contributor.authorIson, M. G.en_US
dc.contributor.authorKaul, D.en_US
dc.contributor.authorMichaels, M. G.en_US
dc.contributor.authorMorris, M. I.en_US
dc.contributor.authorSchwartz, B. S.en_US
dc.contributor.authorEchenique, I. A.en_US
dc.contributor.authorBlumberg, E. A.en_US
dc.date.accessioned2014-05-23T15:59:22Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-05-23T15:59:22Z
dc.date.issued2014-05en_US
dc.identifier.citationLevi, M. E.; Kumar, D.; Green, M.; Ison, M. G.; Kaul, D.; Michaels, M. G.; Morris, M. I.; Schwartz, B. S.; Echenique, I. A.; Blumberg, E. A. (2014). "Considerations for Screening Live Kidney Donors for Endemic Infections: A Viewpoint on the UNOS Policy." American Journal of Transplantation 14(5): 1003-1011.en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106883
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherClinical Research/Practiceen_US
dc.subject.otherInfectious Diseaseen_US
dc.subject.otherDonors and Donationen_US
dc.subject.otherDonor‐Derived Infectionsen_US
dc.subject.otherDonor Evaluationen_US
dc.titleConsiderations for Screening Live Kidney Donors for Endemic Infections: A Viewpoint on the UNOS Policyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106883/1/ajt12666.pdf
dc.identifier.doi10.1111/ajt.12666en_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferencePlanitzer CB, Modrof J, Kreil TR. West Nile virus neutralization by US plasma‐derived immunoglobulin products. J Infect Dis 2007; 196: 435 – 440.en_US
dc.identifier.citedreferenceZou S, Foster GA, Dodd RY, Petersen LR, Stramer SL. West Nile fever characteristics among viremic persons identified through blood donor screening. J Infect Dis 2010; 202: 1354 – 1361.en_US
dc.identifier.citedreferenceBusch MP, Caglioti S, Robertson EF, et al. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005; 353: 460 – 467.en_US
dc.identifier.citedreferenceNett RJ, Kuehnert MJ, Ison MG, Orlowski JP, Fischer M, Staples JE. Current practices and evaluation of screening solid organ donors for West Nile virus. Transpl Infect Dis 2012; 14: 268 – 277.en_US
dc.identifier.citedreferenceInsert NDP: Procleix® WNVAssay (April 20, 2013). Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm090247.pdf. Accessed December 14, 2013.en_US
dc.identifier.citedreferenceLinnen JM, Deras ML, Cline J, et al. Performance evaluation of the PROCLEIX West Nile virus assay on semi‐automated and automated systems. J Med Virol 2007; 79: 1422 – 1430.en_US
dc.identifier.citedreferencePai A, Kleinman S, Malhotra K, Lee‐Haynes L, Pietrelli L, Saldanha J. Performance characteristics of the Food and Drug Administration‐licensed Roche Cobas TaqScreen West Nile virus assay. Transfusion 2008; 48: 2184 – 2189.en_US
dc.identifier.citedreferenceInsert: RMSIP. cobas® TaqScreen West Nile Virus Test for use on the cobas s 201 system.en_US
dc.identifier.citedreferenceRoehrig JT, Nash D, Maldin B, et al. Persistence of virus‐reactive serum immunoglobulin m antibody in confirmed West Nile virus encephalitis cases. Emerg Infect Dis 2003; 9: 376 – 379.en_US
dc.identifier.citedreferenceBusch MP, Kleinman SH, Tobler LH, et al. Virus and antibody dynamics in acute West Nile virus infection. J Infect Dis 2008; 198: 984 – 993.en_US
dc.identifier.citedreferenceCarson PJ, Prince HE, Biggerstaff BJ, Lanciotti R, Tobler LH, Busch M. Characteristics of antibody responses in West Nile virus seropositive blood donors. J Clin Microbiol 2014; 52: 57 – 60.en_US
dc.identifier.citedreferenceCenter for Biologics Evaluation and Research FDA. Guidance for industry: Assessing donor suitability and blood product safety in cases of known or suspected West Nile virus infection. Available at: http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm074111.htm. Accessed June 16, 2013.en_US
dc.identifier.citedreferenceBen‐Nathan D, Gershoni‐Yahalom O, Samina I, et al. Using high titer West Nile intravenous immunoglobulin from selected Israeli donors for treatment of West Nile virus infection. BMC Infect Dis 2009; 9: 18.en_US
dc.identifier.citedreferencePlanitzer CB, Modrof J, Yu MY, Kreil TR. West Nile virus infection in plasma of blood and plasma donors United States. Emerg Infect Dis 2009; 15: 1668 – 1670.en_US
dc.identifier.citedreferenceSaquib R, Randall H, Chandrakantan A, Spak CW, Barri YM. West Nile virus encephalitis in a renal transplant recipient: The role of intravenous immunoglobulin. Am J Kidney Dis 2008; 52: e19 – e21.en_US
dc.identifier.citedreferenceFocus Diagnostics, Package insert: West Nile Virus IgM Capture DxSelect™ (English) Enzyme‐linked Immunosorbent Assay (ELISA) Product Code EL 0300M. (April 18, 2013); Rev. M. Available at: http://www.focusdx.com/pdfs/pi/US/EL0300M.pdf. Accessed February 6, 2014.en_US
dc.identifier.citedreferenceMalan AK, Stipanovich PJ, Martins TB, Hill HR, Litwin CM. Detection of IgG and IgM to West Nile virus. Development of an immunofluorescence assay. Am J Clin Pathol 2003; 119: 508 – 515.en_US
dc.identifier.citedreferenceMalan AK, Martins TB, Hill HR, Litwin CM. Evaluations of commercial West Nile virus immunoglobulin G (IgG) and IgM enzyme immunoassays show the value of continuous validation. J Clin Microbiol 2004; 42: 727 – 733.en_US
dc.identifier.citedreferenceHogrefe WR, Moore R, Lape‐Nixon M, Wagner M, Prince HE. Performance of immunoglobulin G (IgG) and IgM enzyme‐linked immunosorbent assays using a West Nile virus recombinant antigen (preM/E) for detection of West Nile virus‐ and other flavivirus‐specific antibodies. J Clin Microbiol 2004; 42: 4641 – 4648.en_US
dc.identifier.citedreferenceFocus Diagnostics, Package insert: West Nile Virus IgG DxSelect™ Enzyme‐linked Immunosorbent Assay (ELISA) Product Code EL 0300G‐5 (April 18, 2013); Rev. F. Available at: http://www.focusdx.com/pdfs/pi/US/EL0300G‐5.pdf. Accessed February 6, 2014.en_US
dc.identifier.citedreferenceInBios International Inc. Package insert: West Nile Detect™ IgM Capture ELISA for In Vitro Diagnostic Use. 2012 (April 18, 2013). Available at: http://www.inbios.com/cms/file/900015‐05%20%20IVD%20West%20Nile%20Detect%20IgM%20Capture%20ELISA%20Human%20Insert.pdf. Accessed February 6, 2014.en_US
dc.identifier.citedreferencePanbio diagnostics. PANBIO WNV IgM Capture ELISA Package insert (April 18, 2013).en_US
dc.identifier.citedreferencePanbio diagnostics. PANBIO WNV IgG Capture ELISA Package insert. (April 18, 2013).en_US
dc.identifier.citedreferenceSpectral Diagnostics, Inc. 510 (k) Summary of safety and effectiveness: Spectral West Nile IgM STATus™ Test (June 9, 2013). Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf5/k052519.pdf. Accessed February 6, 2014.en_US
dc.identifier.citedreferenceNovartis Diagnostics, Package insert: Procleix® WNVAssay (April 20, 2013). Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/ucm090247.pdf. Accessed February 6, 2014.en_US
dc.identifier.citedreferenceBusch MP, Tobler LH, Saldanha J, et al. Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003. Transfusion 2005; 45: 492 – 499.en_US
dc.identifier.citedreferenceRoche Molecular Systems Inc. Package insert: cobas® TaqScreen West Nile Virus Test for use on the cobas s 201 system (April 20, 2013). Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM091938.pdf. Accessed February 6, 2014.en_US
dc.identifier.citedreferenceNetwork OPaT. Living Donation 2013 (updated May 31, 2013). Available at: http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_172.pdf. Accessed July 16, 2013.en_US
dc.identifier.citedreferenceRoxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis 2009; 49: 1411 – 1423.en_US
dc.identifier.citedreferenceStarr MC, Montgomery SP. Soil‐transmitted Helminthiasis in the United States: A systematic review—1940–2010. Am J Trop Med Hyg 2011; 85: 680 – 684.en_US
dc.identifier.citedreferenceSiddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001; 33: 1040 – 1047.en_US
dc.identifier.citedreferenceAbanyie FBE, Montgomery S, Kuehnert M, Hocevar S, Chin‐Hong P. Donor‐derived Strongyloidiasis in transplant recipients—United States 2009–2012. Am J Transplant 2013; 13 (Suppl 5): 139.en_US
dc.identifier.citedreferenceIgual‐Adell R, Oltra‐Alcaraz C, Soler‐Company E, Sanchez‐Sanchez P, Matogo‐Oyana J, Rodriguez‐Calabuig D. Efficacy and safety of ivermectin and thiabendazole in the treatment of Strongyloidiasis. Expert Opin Pharmacother 2004; 5: 2615 – 2619.en_US
dc.identifier.citedreferenceSchwartz BS, Mawhorter SD. Parasitic infections in solid organ transplantation. Am J Transplant 2013; 13: 280 – 303.en_US
dc.identifier.citedreferenceHuprikar S, Bosserman E, Patel G, et al. Donor‐derived Trypanosoma cruzi infection in solid organ recipients in the United States, 2001–2011. Am J Transplant 2013; 13: 2418 – 2425.en_US
dc.identifier.citedreferenceRiarte A, Luna C, Sabatiello R, et al. Chagas' disease in patients with kidney transplants: 7 Years of experience 1989–1996. Clin Infect Dis 1999; 29: 561 – 567.en_US
dc.identifier.citedreferenceChin‐Hong PV, Schwartz BS, Bern C, et al. Screening and treatment of Chagas disease in organ transplant recipients in the United States: Recommendations from the chagas in transplant working group. Am J Transplant 2011; 11: 672 – 680.en_US
dc.identifier.citedreferenceBern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011; 364: 2527 – 2534.en_US
dc.identifier.citedreferenceKransdorf EP, Czer LS, Luthringer DJ, et al. Heart transplantation for chagas cardiomyopathy in the United States. Am J Transplant 2013; 13: 3262 – 3268.en_US
dc.identifier.citedreferenceQvarnstrom Y, Schijman AG, Veron V, Aznar C, Steurer F, da Silva AJ. Sensitive and specific detection of Trypanosoma cruzi DNA in clinical specimens using a multi‐target real‐time PCR approach. PLoS Negl Trop Dis 2012; 6: e1689.en_US
dc.identifier.citedreferenceHayes EB, Komar N, Nasci RS, Montgomery SP, O'Leary DR, Campbell GL. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis 2005; 11: 1167 – 1173.en_US
dc.identifier.citedreferenceKumar D, Prasad GV, Zaltzman J, Levy GA, Humar A. Community‐acquired West Nile virus infection in solid‐organ transplant recipients. Transplantation 2004; 77: 399 – 402.en_US
dc.identifier.citedreferenceSingh N, Levi ME. Arenavirus and West Nile virus in solid organ transplantation. Am J Transplant 2013; 13: 361 – 371.en_US
dc.identifier.citedreferenceIwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. New Engl J Med 2003; 348: 2196 – 2203.en_US
dc.identifier.citedreferencePealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. New Engl J Med 2003; 349: 1236 – 1245.en_US
dc.identifier.citedreferenceRhee C, Eaton EF, Concepcion W, Blackburn BG. West Nile virus encephalitis acquired via liver transplantation and clinical response to intravenous immunoglobulin: Case report and review of the literature. Transpl Infect Dis 2011; 13: 312 – 317.en_US
dc.identifier.citedreferencePlanitzer CB, Modrof J, Kreil TR. West Nile virus neutralization by US plasma‐derived immunoglobulin products. MMWR Morb Mortal Wkly Rep 2005; 54: 1021 – 1023.en_US
dc.identifier.citedreferenceBlau DM, Rabe IB, Bhatnagar J, et al. West Nile virus RNA in tissues from donor associated with transmission to organ transplant recipients. Emerg Infect Dis 2013; 19: 1518 – 1520.en_US
dc.identifier.citedreferenceCosta AN, Capobianchi MR, Ippolito G, et al. West Nile virus: The Italian national transplant network reaction to an alert in the north‐eastern region, Italy 2011. Euro Surveill 2011; 16: e19 – e21.en_US
dc.identifier.citedreferenceInojosa WO, Scotton PG, Fuser R, et al. West Nile virus transmission through organ transplantation in north‐eastern Italy: A case report and implications for pre‐procurement screening. Infection 2012; 40: 557 – 562.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ajt12666.pdf
Size:
528.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.